-+ 0.00%
-+ 0.00%
-+ 0.00%

UNITY BIOTECHNOLOGY ANNOUNCES COMPLETE 36-WEEK RESULTS FROM THE ASPIRE PHASE 2B STUDY OF UBX1325 IN DIABETIC MACULAR EDEMA AND PROVIDES CORPORATE UPDATES

Reuters·05/05/2025 12:00:02

Please log in to view news